An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

ABSTRACT:

Background

There are known differences in vaccine reactogenicity and immunogenicity by sex. Females have been shown to report greater reactogenicity and generate higher humoral and cellular immune responses than males following vaccination with several different vaccines. Whether this is also the case for COVID-19 vaccines is currently unknown, as COVID-19 vaccine study data disaggregated by sex are not routinely reported. Therefore, we have assessed the influence of sex on reactogenicity, immunogenicity and efficacy of COVID-19 vaccine ChAdOx1 nCoV-19.

Methods

Vaccine efficacy was assessed in 15169 volunteers enrolled into single-blind randomised controlled trials of ChAdOx1 nCoV-19 in Brazil and the UK, with the primary endpoint defined as nucleic acid amplification test (

SUBMITTER: Marchevsky NG 

PROVIDER: S-EPMC9242842 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature